Risk Minimisation Materials
Search by company, common medicine name, or title of Risk Minimisation Material
Zeposia
Bristol Myers Squibb Pharmaceuticals limited
This risk minimisation material is a condition of the marketing authorisation. The Prescriber's Checklist includes information on the ozanimod treatment initiation criteria (including re-initiation); monitoring parameters prior to, during and after treatment with ozanimod, counselling points for patients and pregnancy prevention for women of childbearing potential.
Zeposia (ozanimod) Patient/Caregiver Guide
This risk minimisation material is a condition of the marketing authorisation. This guide should be provided to patients, or caregivers of patients, receiving treatment with ozanimod as it provides important information including what patients need to be aware of before they start taking ozanimod, the signs and symptoms of important side effects they need to look out for during treatment and how to report side effects.
Zeposia (ozanimod) Pregnancy-specific Patient Reminder Card
This risk minimisation material is a condition of the marketing authorisation. This card should be provided to women of childbearing potential receiving treatment with ozanimod. It contains information on the potential risks if ozanimod is used during pregnancy, how to minimise these risks through pregnancy prevention and what the patient should do if they become pregnant while on treatment with ozanimod.
Zessly
Sandoz Limited
Zeyzelf
Luye Pharma Limited
Rivastigmine patch (Zeyzelf) - Instructions for use and patient diary - for patients
Instructions for use and a patient diary including medication record sheets for patients that have been prescribed Zeyzelf Patch (rivastigmine transdermal system) to ensure the correct use of the patch.
Ziagen
ViiV Healthcare UK Ltd
Abacavir Hypersensitivity Website for Healthcare Professionals
Abacavir Hypersensitivity Website for Healthcare Professionals
Zilbrysq
UCB Pharma Limited
Zilbrysq Guide for Healthcare Professionals
This guide is for healthcare professionals who will prescribe or dispense ZILBRYSQ
(zilucoplan). It describes:
• The potential increased risk of meningococcal infections with zilucoplan
• How you can mitigate this risk by ensuring patients receive recommended meningococcal
vaccinations and, if needed, antibiotic therapy
• Important information for starting a patient on zilucoplan
• How to counsel patients with the Patient/Carer Guide and Patient Alert Card
Zilbrysq Patient Carer Guide
This is a guide for patients who use zilucoplan and for those who care for them. It contains important
safety information about the use of zilucoplan.
Zoledronic acid
Bowmed Ibisqus Limited
Zoledronic acid - Patient alert card
This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid
Dr. Reddy's Laboratories (UK) Ltd
Zoledronic acid 5mg/100ml solution for infusion patient reminder card
The reminder card contains important information that you need to be aware of before and during treatment with zoledronic acid (5mg solution for infusion).
Ennogen Healthcare Ltd
Zoledronic acid - Patient Reminder Card
This reminder card contains important safety information
that you need to be aware of before and during treatment
with Zoledronic acid Ennogen 4 mg/5 ml concentrate for
solution for infusion for cancer-related conditions.
Martindale Pharma, an Ethypharm Group Company
Zoledronic acid patient card
Zoledronic Acid Patient Card
This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid (4mg/100ml solution for infusion;
4mg/5ml concentrate for solution for infusion) injections for cancer-related conditions.
Zoledronic Acid Patient Card
Zoledronic Acid Patient Card
This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid (5mg solution for infusion).
Morningside Healthcare Ltd
Mylan
Patient Reminder Card for osteonecrosis of the jaw
Patient reminder card for osteonecrosis of the jaw before and during treatment with zoledronic acid (4mg/100ml solution for infusion; 4mg/5ml concentrate for solution for infusion) injections
Ranbaxy (UK) Limited a Sun Pharmaceutical Company
Zoledronic Acid 5 mg solution for infusion - ONJ
Zoledronic Acid 5 mg solution for infusion - ONJ - patient reminder card
Seacross Pharmaceuticals Ltd
DOCTOR'S INFORMATION GUIDE
This information is part of the Risk Management Plan (RMP) for Zoledronic acid Seacross 5mg/100ml solution for infusion (hereafter refers as Zoledronic acid Seacross 5mg/100ml), and aims at minimisation of identified and potential therapy-related risks in order to optimize the benefit/risk balance. For complete information read the registered Summary of Product Characteristics of Zoledronic acid Seacross 5 mg/100ml before you prescribe Zoledronic acid Seacross 5mg/100ml.
ONJ-Patient Reminder Card
This reminder card containsimportant safety information that you need to be aware of before and during treatment with zoledronic acid(4mg/5ml,concentrate for solution for infusion; 4mg/100ml, solution for infusion)injections for cancer-related conditions
PATIENT INFORMATION GUIDE
This brochure is intended for patients with an increased risk of bone fractures that are going to be treated with Zoledronic acid Seacross 5mg/100ml solution for infusion(Hereafter refer as Zoledronic acid Seacross 5mg/100ml). Read this brochure carefully because it gives you important information about Zoledronic acid Seacross 5mg/100ml. Please also read the package leaflet ofZoledronic acid Seacross 5mg/100ml for more information.
PATIENT REMINDER CARD
This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid Seacross 5mg/100ml solution for infusion.
Tillomed Laboratories Ltd
Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion
This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid 4 mg/5 ml concentrate for solution for infusion for cancer-related conditions.
Zolgensma
Novartis Pharmaceuticals UK Ltd
Zolgensma Healthcare Professional Guide
A healthcare professional’s guide to minimizing risks with Zolgensma
Zometa
Phoenix Labs
Zometa (Zoledronic Acid) Patient Reminder Card
The reminder card contains important information that you need to be aware of before and during treatment with zoledronic acid (Zometa) injections.
Zynlonta
Swedish Orphan Biovitrum Ltd
Zynlonta - Patient Card - NP-28941
This patient alert card contains important safety information that patients need to be aware of during treatment with ZYNLONTA, including the risk of photosensitivity reactions.
Zypadhera
Eli Lilly and Company Limited
ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection Patient Alert Card
ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection Patient Alert Card containing important safety information for patients.
Neon Healthcare Ltd
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?